Loading company…
Notch Therapeutics develops stem cell-derived immunotherapies, including gene-edited immune cell treatments.
Founded in 2018 in Toronto, Notch Therapeutics develops cellular immunotherapies intended to produce T cells and other immune cells from clonal stem cells. In February 2021, it raised USD 85 million in Series A funding from Allogene Therapeutics, Inc., Lumira Ventures, CCRM Enterprises Holdings Ltd., EcoR1 Capital, Casdin Capital, Samsara BioCapital, and Amplitude Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in